ArticleFrontiers in bioengineering and biotechnology2026
RuBisCO-based CO
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and introduction: Efficiently harnessing CO Methods: In this study, we engineered the industrial glutamate-hyperproducing strain Results: Comparative analysis revealed that the "replacement" strategy severely impaired cell growth and glutamate synthesis, with ALE failing to restore the desired production levels. In contrast, the "complementation" strategy significantly enhanced metabolic performance. The optimized strain GluE014 exhibited superior carbon-to-product conversion, achieving a glutamate titer of 196.78 g/L in a 5 L fed-batch fermenter within 30 h. This represents a 13.94% increase in titer and an 11.55% improvement in glucose-based yield compared to the parental strain. Furthermore, the engineered strain demonstrated improved carbon economy, reducing glucose consumption by 5.24% while maintaining high productivity. Conclusion: This work demonstrates that "complementing" native metabolism with a CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.